Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer
Based on Initial Positive Data, Exai to Study a Larger Cohort of Patients to Evaluate oncRNAs as a Predictive and Prognostic Biomarker Across Multiple Therapies PALO ALTO, Calif.–(BUSINESS WIRE)–Exai Bio today announced a collaboration agreement with Quantum Leap Healthcare Collaborative™ (QLHC) to broaden the use of Exai’s novel, RNA-based liquid biopsy platform to monitor patients’ … [Read more…]
